Citations

Showing 10 of 108119 citations.

Review article: iron disturbances in chronic liver diseases other than haemochromatosis – pathogenic, prognostic, and therapeutic implications
Czaja, Albert J.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 14, 2019 | Volume: 49 | Issue: 6 | Pages: 681-701

10.1111/apt.15173 | PMID 30761559 Get It

SummaryBackgroundDisturbances in iron regulation have been described in diverse chronic liver diseases other than hereditary haemochromatosis, and iron toxicity may worsen liver injury and outcome.AimsTo describe manifestations and consequences of iron dysregulation in chronic liver diseases apart from hereditary haemochromatosis and to encourage investigations that clarify pathogenic mechanisms, define risk thresholds for iron toxicity, and direct managementMethodsEnglish abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed.ResultsHyperferritinemia is present in 4%‐65% of patients with non‐alcoholic fatty liver disease, autoimmune hepatitis, chronic viral hepatitis, or alcoholic liver disease, and hepatic iron content is increased in 11%‐52%. Heterozygosity for the C282Y mutation is present in 17%‐48%, but this has not uniformly distinguished patients with adverse outcomes. An inappropriately low serum hepcidin level has characterised most chronic liver diseases with the exception of non‐alcoholic fatty liver disease, and the finding has been associated mainly with suppression of transcriptional activity of the hepcidin gene. Iron overload has been associated with oxidative stress, advanced fibrosis and decreased survival, and promising therapies beyond phlebotomy and oral iron chelation have included hepcidin agonists.ConclusionsIron dysregulation is common in chronic liver diseases other than hereditary haemochromatosis, and has been associated with liver toxicity and poor prognosis. Further evaluation of iron overload as a co‐morbid factor should identify the key pathogenic disturbances, establish the risk threshold for iron toxicity, and promote molecular interventions.
Cellular Dermatofibroma: Clinicopathologic Review of 218 Cases of Cellular Dermatofibroma to Determine the Clinical Recurrence Rate
Gaufin, Meredith, Michaelis, Timothy C, Duffy, Keith L. , Michaelis, Timothy

Mayo Clinic

Dermatologic Surgery | February 14, 2019 | Volume: 45 | Issue: 11 | Pages: 1359-1364

10.1097/dss.0000000000001833 | PMID 30741794 Get It

BACKGROUND Cellular dermatofibromas, a variant of dermatofibroma, are reported to recur at rates of 26% to 50%. OBJECTIVE To determine whether there are distinct clinical or histological differences between cellular dermatofibromas that recur versus those that do not. To determine recurrence rates in a real-world clinical setting. MATERIALS AND METHODS A retrospective analysis of the medical records and skin biopsies of cellular dermatofibroma in the University of Utah Health system between December 2011 and 2016. Clinical and dermatopathological features were evaluated to find distinct differences between the cellular dermatofibromas that recurred compared with those that did not. RESULTS There were no significant differences in histology between the primary lesions in recurrent and nonrecurrent cases. One factor that seemed to be associated with a greater likelihood of recurrence was an initial lesion size greater than 1 cm. The authors' data suggest that if the margins are involved on initial biopsy, there is a 10% chance of recurrence. This percentage is far less than the 26% to 50% reported in the past literature. CONCLUSION If a patient presents with a cellular dermatofibroma larger than 1 cm and positive margins at initial biopsy, a careful discussion should be had between the provider and patient about the low risk of local recurrence.
CORR Insights®: What Is the Possible Impact of High Variability of Distal Femoral Geometry on TKA? A CT Data Analysis of 24,042 Knees
Spangehl, Mark J.

Mayo Clinic

Clinical Orthopaedics & Related Research | February 14, 2019 | Volume: 477 | Issue: 3 | Pages: 571-572

10.1097/corr.0000000000000669 | PMID 30762690 Get It

Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
Kotwal, Anupam , Block, Matthew S. , Kudva, Yogish C. , Haddox, Candace, Block, Matthew, Kudva, Yogish C , Haddox, Candace L.

Mayo Clinic

BMJ Open Diabetes Research & Care | February 14, 2019 | Volume: 7 | Issue: 1 | Pages: e000591

10.1136/bmjdrc-2018-000591 | PMID 30899528 Get It

Objective Insulin-dependent diabetes can occur with immune checkpoint inhibitor (ICI) therapy. We aimed to characterize the frequency, natural history and potential predictors of ICI-induced diabetes. Research design and methods We reviewed 1444 patients treated with ICIs over 6 years at our cancer center, and from the 1163 patients who received programmed cell death protein 1 (PD-1) inhibitors, we identified 21 such cases, 12 of which developed new-onset insulin-dependent diabetes and 9 experienced worsening of pre-existing type 2 diabetes. Results ICI-induced diabetes occurred most frequently with pembrolizumab (2.2%) compared with nivolumab (1%) and ipilimumab (0%). The median age was 61 years, and body mass index was 31 kg/m2, which are both higher than expected for spontaneous type 1 diabetes. Other immune-related adverse events occurred in 62%, the most common being immune mediated thyroid disease. New-onset insulin-dependent diabetes developed after a median of four cycles or 5 months; 67% presented with diabetic ketoacidosis and 83% with low or undetectable C-peptide. Autoantibodies were elevated in 5/7 (71%) at the time of new-onset diabetes. Diabetes did not resolve during a median follow-up of 1 year. Conclusions PD-1 inhibitors can lead to insulin deficiency presenting as new-onset diabetes or worsening of pre-existing type 2 diabetes, with a frequency of 1.8 %. The underlying mechanism appears similar to spontaneous type 1 diabetes but there is a faster progression to severe insulin deficiency. Better characterization of ICI-induced diabetes will improve patient care and enhance our understanding of immune-mediated diabetes.
Middle Fossa Approach With Anterior Petrosectomy for Resection of a Meningioma Mimicking a Trigeminal Schwannoma, a Step-by-Step Surgical and Anatomical Description: 2-Dimensional Operative Video
Peris‐Celda, Maria , Carlstrom, Lucas P. , Perry, Avital , Graffeo, Christopher S. , Driscoll, Colin L. W., Link, Michael J. , Driscoll, Colin L.

Mayo Clinic

Operative Neurosurgery | February 14, 2019 | Volume: 17 | Issue: 1 | Pages: E12-E13

10.1093/ons/opy313 | PMID 31197348 Get It

Abstract Selected upper cerebellopontine angle (CPA)/petroclival region lesions can be visualized and resected through a middle fossa approach with anterior petrosectomy. This approach is particularly well suited for tumors that extend from the CPA into Meckel's cave or the middle cranial fossa. We present the case of a 55-yr-old man who presented with sudden left-sided hearing loss, with complete recovery after medical treatment. MRI demonstrated a left 1.8 cm contrast-enhancing upper CPA lesion with extension into Meckel's cave most consistent with a trigeminal schwannoma. The patient initially opted for observation. MRI 11 mo later showed notable enlargement in the tumor, and the patient started to experience left-sided neuralgic face pain. The decision was made to perform surgery. Documented and verified informed consent was obtained A step-by-step surgical video with surgical anatomy images highlights the 5 steps followed by the authors to perform an anterior petrosectomy. The dura mater was opened parallel to the superior petrosal sinus both in the infratentorial and supratentorial spaces in order to clip and coagulate the superior petrosal sinus and divide the tentorium. The lesion was fully visualized and the trigeminal nerve was clearly identified displaced inferiorly but not splayed by the tumor, making the diagnosis of trigeminal schwannoma unlikely. The lesion was debulked and dissected off the brainstem as well as the trigeminal nerve with the final view of intact nerve fascicles entering the posterior aspect of Meckel's cave. Pathology returned as a WHO grade 1 meningioma. The patient recovered well with only mild facial hypesthesia and complete tumor resection on follow-up imaging.
A Review of Epigenetics of PTSD in Comorbid Psychiatric Conditions
Blacker, Caren J. , Frye, Mark A. , Kozicz, Tamás , Veldić, Marin , Kozicz, Tamas , Veldic, Marin , Blacker, Caren J , Morava, Éva

Mayo Clinic

Genes | February 14, 2019 | Volume: 10 | Issue: 2 | Pages: 140

10.3390/genes10020140 | PMID 30781888 Get It

Post-traumatic stress disorder (PTSD) is an acquired psychiatric disorder with functionally impairing physiological and psychological symptoms following a traumatic exposure. Genetic, epigenetic, and environmental factors act together to determine both an individual’s susceptibility to PTSD and its clinical phenotype. In this literature review, we briefly review the candidate genes that have been implicated in the development and severity of the PTSD phenotype. We discuss the importance of the epigenetic regulation of these candidate genes. We review the general epigenetic mechanisms that are currently understood, with examples of each in the PTSD phenotype. Our focus then turns to studies that have examined PTSD in the context of comorbid psychiatric disorders or associated social and behavioral stressors. We examine the epigenetic variation in cases or models of PTSD with comorbid depressive disorders, anxiety disorders, psychotic disorders, and substance use disorders. We reviewed the literature that has explored epigenetic regulation in PTSD in adverse childhood experiences and suicide phenotypes. Finally, we review some of the information available from studies of the transgenerational transmission of epigenetic variation in maternal cases of PTSD. We discuss areas pertinent for future study to further elucidate the complex interactions between epigenetic modifications and this complex psychiatric disorder.
Neuro-oncology
Ruff, Michael W. , Uhm, Joon H. , Benarroch, Eduardo E.

Mayo Clinic

Neurology | February 14, 2019 | Volume: 92 | Issue: 12 | Pages: 568-574

10.1212/wnl.0000000000007126 | PMID 30760635 Get It

Lumbosacral radiculoplexus neuropathy
Ng, Peng Soon, Dyck, P. James B. , Laughlin, Ruple S. , Thapa, Prabin , Pinto, Marcus Vinícius , Pinto, Marcus V

Mayo Clinic

Neurology | February 14, 2019 | Volume: 92 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000007020 | PMID 30760636 Get It

Contemporary management of cardiac implantable electronic device infection
Sohail, M. Rizwan , Mulpuru, Siva K. , Sohail, Mohammed Rizwan, Mulpuru, Siva Kiran, Sohail, M Rizwan , DeSimone, Daniel C.

Mayo Clinic

Heart | February 14, 2019 | Volume: 105 | Issue: 12 | Pages: 961-965

10.1136/heartjnl-2017-312146 | PMID 30755468 Get It

Propofol-associated Green Hair Discoloration
Pulos, Bridget P. , Sviggum, Hans P. , Sharpe, Emily E.

Mayo Clinic

Anesthesiology | February 14, 2019 | Volume: 130 | Issue: 3 | Pages: 445-445

10.1097/aln.0000000000002544 | PMID 30664056 Get It